期刊文献+

中晚期肝癌凝血及纤溶功能变化及其临床意义 被引量:3

Clinical significance and cogulation and fibrinolytic function changes in patients with advanced hepatocellular carcinoma
下载PDF
导出
摘要 目的探讨中晚期肝癌凝血及纤溶功能变化及其临床意义。方法对41例中晚期原发性肝癌患者进行凝血及纤溶功能指标的检测,并与42例早期肝癌和36名健康对照组比较。结果血浆凝血酶原时间(PT)水平为中晚期肝癌组高于早期肝癌组,早期肝癌组高于对照组(P<0.01);活化的部分凝血活酶时间(APTT)水平为中晚期肝癌组低于早期肝癌组,早期肝癌组低于对照组(P<0.01);凝血酶时间(TT)水平为中晚期肝癌组与早期肝癌组比较,差异无显著性意义(P>0.05),早期肝癌组高于对照组(P<0.01);纤维蛋白原含量(FIB)水平为肝癌组低于对照组(P<0.01);各组P-选择素(Ps)、尿激酶型纤溶酶原激活物(uPA)和纤溶酶原激活物抑制物(PA1)水平为中晚期肝癌组高于早期肝癌组,早期肝癌组高于对照组(P<0.01或P<0.05);血管性血友病因子(vWF)3组比较差异无显著性意义(P>0.05)。结论中晚期肝癌患者出现凝血及纤溶功能紊乱现象,可能为评价其预后的一项敏感指标,值得进一步研究。 [Objective] To investigate coagulation and fibrinolytic function and clinical significance in patitents with advanced hepatocellular carcinoma. [Methods] Coagulation and fibrinolysis function testing were carried out in 41 patients with advanced hepatocellular carcinoma ,and the results were compared to 42 patients with early liver cancer and 36 healthy persons in control group. [Results] the level of plasma prothrombin time (PT) in advanced hepatoeellular carcinoma group was higher than that in the early HCC control group (P 〈0.01). The level of the activated partial thromboplastin time (APTT) in advanced liver cancer group was lower than that of early HCC. There was no significance between the level of TT in advanced liver cancer group and the level in the early HHC group (P 〉0.05), the level of TT was higher in early HCC group when compared to the control group. The FIB level in liver cancer group was lower than that in control group, the level of P-selectin (Ps), urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PA1) was higher than that in Early HCC, and the level in early HCC was higher than in the heathy control group (P 〈0.01, P 〈0.05), the level of yon WiUebrand factor (vWF) showed no significant difference (P〉0.05) in the three groups. [Conclusions] The coagulation and fibrinolysis dysfunction phenomenon in patients with advanced liver cancer may be a sensitive indicator to evaluate the prognosis and it is worth further study.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2009年第3期430-432,共3页 China Journal of Modern Medicine
基金 广西百色市科技局基金资助项目(No:2004016)
关键词 原发性肝癌 血栓前状态 primary hepatocellular carcinoma PHC prethrombotic state PTS
  • 相关文献

参考文献1

二级参考文献5

  • 1Oleksowicz L, Mrowiec Z, Schwartz E, et al. Characterization of tumor-induced platelet aggregation: the role of immunorelated GP Ⅰb and GPⅡb/Ⅲa expression by MCF-7 breast cancer cells. Thromb Res, 1995, 79: 261-274.
  • 2Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem, 1998, 67: 395-424.
  • 3Oleksowicz L, Bhagwati N, DeLeon-Fernandez M. Dificient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies. Cancer Res, 1999, 59: 2244-2250.
  • 4Lee TE Bouhassira EE, Lyubsky S, et al. ADAMTS13, the von Willebrand factor cleaving metalloprotease, is expressed in the perisinusoidal cells of the liver. Blood, 2002, 100(Suppl.1): 497a.
  • 5Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood,2001, 98: 2730-2735.

共引文献2

同被引文献31

  • 1Mansour A, Ismael Y, Abunasser M, et al. The application of clinical variables and models to predict pulmonary embolism in Cancer patients: a comprehensive single Cancer center experience [ J ]. Patient Prefer Adherence, 2013, 7 : 1111-1116.
  • 2Clayburgh DR, Stott W, Cordiero T, et al. Prospective study of venous thmmboembolism in patients with head and neck Cancer after surgery[J]. JAMA Otolaryngol Head Neck Surg, 2013, 139 (11) : 1143-1150.
  • 3Austin KM, Covic L, Kuliopulos A. Matrix metalloproteases and PAR1 activation[J]. Blood, 2013, 121 (3) : 431-439.
  • 4Korte W. Cancer and thrombosis: an increasingly important association[J]. Support Care Cancer, 2005, 16 (3) : 223-228.
  • 5Timp JF, Braekkan SK, Versteeg HH. Epidemiology of cancer- associated venousthrombosis[J].Blood, 2013, 122 (10): 1712- 1723.
  • 6Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors[J]. Breast Cancer, 2005, 12 (1): S16-S27.
  • 7L6pez JA, Kearon C, Lee AY. Deep venous thrombosis [J]. Hematology Am Soe Hematol Educ Program, 2004: 439-456.
  • 8Zincircioglu SB, Kaplan MA, Isikdogan A, et al. Contribution of low-molecular weight heparin addition to concomitant chemoradiotherapy in the treatment of glioblastoma multiforme [J]. J BUON, 2012, 17 (1): 124-127.
  • 9Kucukoner M, Isikdogan A, Kaplan MA, et al. Can LMWH improve the outcome of patients with inoperable stage III non-small cell lung Cancer? [J]. Contemp Oneol (Pozn), 2012, 16 (5) :416-419.
  • 10Pingsheng Fan, Tengyue Zhang, Qiang Huang, et al. Basic and clinical research on the therapeutic effect of intervention in primary liver Cancer by targeted intra-arterial verapamil infusion [J]. Cell BiochemBiophys, 2012, 62 (1): 59-67.

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部